Two Major Drug Safety Databases Flag Eye Risks with GLP-1 Drugs | Research

The takeaway

Advanced signal detection across both FAERS and VigiBase databases identifies and characterizes ocular adverse event signals associated with GLP-1 receptor agonists.

Dual-database eye risk analysis
Advanced signal mining in both FAERS and VigiBase for GLP-1 RA ocular safety

What the researchers found

Multi-database pharmacovigilance analysis using advanced signal detection identified and characterized ocular toxicity signals associated with GLP-1 RAs across both FAERS and VigiBase.

Why it matters

Tens of millions use GLP-1 drugs. Systematically detecting eye risks across the world's two largest drug safety databases provides the strongest real-world safety signal assessment possible.

How the study worked

Pharmacovigilance study using advanced signal mining across FDA FAERS and WHO VigiBase databases for GLP-1 RA ocular adverse events.

What this study cannot tell us

Pharmacovigilance databases rely on voluntary reporting; cannot determine causation or true incidence; signal detection identifies associations requiring clinical confirmation.

How to read the evidence

Advanced pharmacovigilance analysis across two major databases — strongest available real-world safety signal detection methodology.

When this study was published

Published in 2026, providing the most comprehensive GLP-1 ocular safety analysis using global pharmacovigilance data.

The bigger picture

As GLP-1 drugs become the most prescribed drug class globally, comprehensive safety surveillance across international databases is essential for protecting the massive population of users.

Questions still open

Should ophthalmologic screening be recommended for GLP-1 drug users based on these signals?
Are ocular risks dose-dependent or related to specific GLP-1 agents?

Common questions

Do GLP-1 drugs cause eye problems?

This study found safety signals for eye-related side effects in two major drug safety databases. While signals don't prove the drugs cause eye problems, they warrant further investigation and monitoring.

What is pharmacovigilance?

Pharmacovigilance is the science of monitoring drug safety after they're approved. Databases like FAERS and VigiBase collect reports of side effects from doctors and patients worldwide to detect safety concerns.

Read the original research

Multi-database pharmacovigilance assessment of GLP-1 receptor agonist-related ophthalmic risks using advanced signal detection in FAERS and vigibase.

Journal of endocrinological investigation, 49(2), 425-433

View on PubMed ↗Publisher’s paper ↗

Citation

Cheng, Xiao; Jiang, Ziwei; Li, Guangyao; Wang, Jiawei; Han, Furong. (2026). Multi-database pharmacovigilance assessment of GLP-1 receptor agonist-related ophthalmic risks using advanced signal detection in FAERS and vigibase.. Journal of endocrinological investigation, 49(2), 425-433. https://doi.org/10.1007/s40618-025-02712-3